Andros Pharmaceutical
Taipei, Taiwan· Est.
Taiwanese biotech creating liposome‑based topical and non‑viral gene delivery platforms for pain and gene‑therapy indications.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwanese biotech creating liposome‑based topical and non‑viral gene delivery platforms for pain and gene‑therapy indications.
Pain ManagementDNA RepairGene Therapy
Technology Platform
Proprietary liposome‑based topical formulations and non‑viral lipid‑nanoparticle gene delivery vectors enabling targeted, controlled release of therapeutics.
Opportunities
Successful Phase IIb/III data could unlock licensing deals with global pharma and expand the platform into additional therapeutic areas such as oncology and rare genetic diseases.
Risk Factors
Reliance on a single lead candidate and limited financial resources pose execution risk; regulatory setbacks or trial failures could significantly delay commercialization.
Competitive Landscape
Andros competes with both large pharma and niche biotech firms in drug delivery; its integrated topical and gene‑delivery platform offers differentiation but must prove superiority in efficacy and safety.